Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201


RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome.

Abbar B, Henry C, Theou-Anton N, Brosseau S, Nguenang M, Pluvy J, Assoun S, Zalcman G, Gounant V.

J Thorac Oncol. 2019 Nov;14(11):e250-e251. doi: 10.1016/j.jtho.2019.06.008. No abstract available.


Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Oct 4. pii: mdz407. doi: 10.1093/annonc/mdz407. [Epub ahead of print]


STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes.

Martin AP, Jacquemyn M, Lipecka J, Chhuon C, Aushev VN, Meunier B, Singh MK, Carpi N, Piel M, Codogno P, Hergovich A, Parrini MC, Zalcman G, Guerrera IC, Daelemans D, Camonis JH.

EMBO Rep. 2019 Nov 5;20(11):e48150. doi: 10.15252/embr.201948150. Epub 2019 Sep 23.


Trials of Prophylactic Irradiation of Tracts: What is the Appropriate End Point?

Zalcman G, Brosseau S, Gounant V.

J Clin Oncol. 2019 Oct 10;37(29):2693. doi: 10.1200/JCO.19.00927. Epub 2019 Aug 22. No abstract available.


Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.

Clin Lung Cancer. 2019 Sep;20(5):e564-e575. doi: 10.1016/j.cllc.2019.04.010. Epub 2019 May 13.


Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Léna H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V; French Cooperative Thoracic Intergroup (IFCT).

Clin Cancer Res. 2019 Oct 1;25(19):5759-5765. doi: 10.1158/1078-0432.CCR-18-2860. Epub 2019 Jun 7.


Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]


Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.

Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, Pluvy J, Gounant V, Khalil A, Namour C, Brosseau S, Zalcman G.

Lung Cancer. 2019 Jun;132:65-71. doi: 10.1016/j.lungcan.2019.04.005. Epub 2019 Apr 8.


Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas.

Levallet G, Creveuil C, Bekaert L, Péres E, Planchard G, Lecot-Cotigny S, Guillamo JS, Emery E, Zalcman G, Lechapt-Zalcman E.

J Mol Diagn. 2019 Jul;21(4):695-704. doi: 10.1016/j.jmoldx.2019.03.007. Epub 2019 May 2.


NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells.

Keller M, Dubois F, Teulier S, Martin APJ, Levallet J, Maille E, Brosseau S, Elie N, Hergovich A, Bergot E, Camonis J, Zalcman G, Levallet G.

J Exp Clin Cancer Res. 2019 Apr 12;38(1):158. doi: 10.1186/s13046-019-1145-8.


Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.

Duplaquet L, Figeac M, Leprêtre F, Frandemiche C, Villenet C, Sebda S, Sarafan-Vasseur N, Bénozène M, Vinchent A, Goormachtigh G, Wicquart L, Rousseau N, Beaussire L, Truant S, Michel P, Sabourin JC, Galateau-Sallé F, Copin MC, Zalcman G, De Launoit Y, Fafeur V, Tulasne D.

Mol Cancer Ther. 2019 Jun;18(6):1137-1148. doi: 10.1158/1535-7163.MCT-18-0582. Epub 2019 Mar 29.


MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.

Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.


Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchampt E, Morin F, Zalcman G, Pignon JP, Cadranel J.

Clin Lung Cancer. 2019 May;20(3):222-230. doi: 10.1016/j.cllc.2018.12.012. Epub 2018 Dec 19.


Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup.

Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: Lancet Oncol. 2019 Mar;20(3):e132.


Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.

Pluvy J, Brosseau S, Stelianides S, Danel C, Nguenang M, Khalil A, Crestani B, Zalcman G, Gounant V.

BMC Pulm Med. 2019 Jan 11;19(1):12. doi: 10.1186/s12890-018-0775-5.


Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).

Chouaid C, Salaün M, Gounant V, Febvre M, Vergnon JM, Jouniaux V, Fournier C, Lachkar S, Hermant C, Raspaud C, Quantin X, Quiot JJ, Molard A, Dayen C, Marquette CH, Lena H, Zalcman G, Thiberville L.

PLoS One. 2019 Jan 7;14(1):e0208992. doi: 10.1371/journal.pone.0208992. eCollection 2019.


Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments.

Nguyen M, De Ninno A, Mencattini A, Mermet-Meillon F, Fornabaio G, Evans SS, Cossutta M, Khira Y, Han W, Sirven P, Pelon F, Di Giuseppe D, Bertani FR, Gerardino A, Yamada A, Descroix S, Soumelis V, Mechta-Grigoriou F, Zalcman G, Camonis J, Martinelli E, Businaro L, Parrini MC.

Cell Rep. 2018 Dec 26;25(13):3884-3893.e3. doi: 10.1016/j.celrep.2018.12.015.


Management of immune-related adverse events resulting from immune checkpoint blockade.

Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group.

Expert Rev Anticancer Ther. 2019 Mar;19(3):209-222. doi: 10.1080/14737140.2019.1562342. Epub 2019 Jan 9.


CaMKII Isoforms in Learning and Memory: Localization and Function.

Zalcman G, Federman N, Romano A.

Front Mol Neurosci. 2018 Dec 4;11:445. doi: 10.3389/fnmol.2018.00445. eCollection 2018. Review.


A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control.

Dubois F, Jean-Jacques B, Roberge H, Bénard M, Galas L, Schapman D, Elie N, Goux D, Keller M, Maille E, Bergot E, Zalcman G, Levallet G.

Cell Commun Signal. 2018 Oct 11;16(1):66. doi: 10.1186/s12964-018-0276-4.


[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.

Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. French.


Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.


Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clément-Duchêne C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazières J, Besse B, Girard N.

J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.


(J)ALEX the great: a new era in the world of ALK inhibitors.

Brosseau S, Gounant V, Zalcman G.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2138-S2143. doi: 10.21037/jtd.2018.06.142. No abstract available.


Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.


Minimal Change Disease Induced by Lorlatinib.

Betton M, Gounant V, Sannier A, Hanouna G, Goujon JM, Brosseau S, Zalcman G, Chemouny JM.

J Thorac Oncol. 2018 Aug;13(8):e154-e156. doi: 10.1016/j.jtho.2018.03.033. No abstract available.


Sustained CaMKII Delta Gene Expression Is Specifically Required for Long-Lasting Memories in Mice.

Zalcman G, Federman N, Fiszbein A, de la Fuente V, Ameneiro L, Schor I, Romano A.

Mol Neurobiol. 2019 Feb;56(2):1437-1450. doi: 10.1007/s12035-018-1144-3. Epub 2018 Jun 9.


Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.


Diagnostic value of quantitative assessment of cardiac 18F-fluoro-2-deoxyglucose uptake in suspected cardiac sarcoidosis.

Lebasnier A, Legallois D, Bienvenu B, Bergot E, Desmonts C, Zalcman G, Agostini D, Manrique A.

Ann Nucl Med. 2018 Jun;32(5):319-327. doi: 10.1007/s12149-018-1250-3. Epub 2018 Mar 20.


Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.


Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.

Brosseau S, Gounant V, Choudat L, Pluvy J, Zalcman G, Khalil A.

Diagn Interv Imaging. 2018 Apr;99(4):267-268. doi: 10.1016/j.diii.2018.01.008. Epub 2018 Feb 19. No abstract available.


Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.


Immunotherapy in relapsed mesothelioma.

Brosseau S, Dhalluin X, Zalcman G, Scherpereel A.

Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144. No abstract available.


Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis.

Bouchery-Bardet H, Creveuil C, Bauer F, Beygui F, Champ-Rigot L, Saloux E, Labombarda F, Roule V, Sabatier R, Legallois D, Zalcman G, Bergot E, Milliez P.

Respir Med. 2017 Nov;132:42-49. doi: 10.1016/j.rmed.2017.09.008. Epub 2017 Sep 22.


Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.


A review of bevacizumab in the treatment of malignant pleural mesothelioma.

Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G.

Future Oncol. 2017 Dec;13(28):2537-2546. doi: 10.2217/fon-2017-0307. Epub 2017 Sep 20. Review.


Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation.

Brosseau S, Gounant V, Naltet C, Théou-Anton N, Cazes A, Smonig R, Neuville M, Khalil A, Mikail N, Meignin V, Bergeron A, Zalcman G.

Clin Lung Cancer. 2018 Jan;19(1):e57-e61. doi: 10.1016/j.cllc.2017.07.003. Epub 2017 Aug 3. No abstract available.


Bevacizumab in advanced lung cancer: state of the art.

Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G.

Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 Aug 16. Review.


EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.


Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.

Pluvy J, Brosseau S, Naltet C, Opsomer MA, Cazes A, Danel C, Khalil A, Zalcman G, Gounant V.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700310. doi: 10.1183/13993003.00310-2017. Print 2017 Jul. No abstract available.


[Current knowledge on perioperative treatments of non-small cell lung carcinomas].

Brosseau S, Naltet C, Nguenang M, Gounant V, Mordant P, Milleron B, Castier Y, Zalcman G.

Rev Mal Respir. 2017 Jun;34(6):618-634. doi: 10.1016/j.rmr.2016.12.001. Epub 2017 Jul 12. Review. French.


Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.

Guyard A, Danel C, Théou-Anton N, Debray MP, Gibault L, Mordant P, Castier Y, Crestani B, Zalcman G, Blons H, Cazes A.

Respir Res. 2017 Jun 15;18(1):120. doi: 10.1186/s12931-017-0605-y.


Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.


Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.


Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.

Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.


First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C.

Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14.


[Therapeutic advances in lung cancer].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Prat. 2017 Jan;67(1):47-50. French.


MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.

Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.


[Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Mal Respir. 2016 Oct;33(8):654-657. doi: 10.1016/j.rmr.2016.10.005. French. No abstract available.


A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

Supplemental Content

Loading ...
Support Center